INNATE PHARMA (EPA:IPH) Half-year report on Innate Pharma's liquidity contract with Natixis Securities

Transparency directive : regulatory news

02/01/2012 20:29

Press release

HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Marseilles, France, January 2, 2012

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities,
the following assets appeared on the liquidity account as at December 31,
2011:

  * 155,175 shares of Innate Pharma, and
  * 34,986.66 euros in cash.

At the implementation of the liquidity contract, the following assets appeared
on the liquidity account:

  * 0 share of Innate Pharma, and
  * 300,000.00 euros in cash.

For information, the following assets appeared on the liquidity account at the
latest report:

  * 121,882 shares of Innate Pharma, and
  * 33,311.37 euros in cash.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with two
major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 81 employees as at September 30, 2011.

Learn more about Innate Pharma at www.innate-pharma.com. Practical Information
about Innate Pharma shares:

ISIN code        FR0010331421
Ticker code      IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                        French enquiries
                                     ATCG Press
Laure-Hélène Mercier                 Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87          Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com          mb@atcg-partners.com

International enquiries M :Communications
Peter Laing, Amber Bielecka,
Hollie Vile
Phone: +44 (0)20 7920 2330
innatepharma@mcomgroup.com

120102 Half-year report on liquidity agreement

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Half-year report on Innate Pharma's liquidity contract with Natixis Securities

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories